Antihypertensive effects of lactoferrin hydrolyzates: Inhibition of angiotensin- and endothelin-converting enzymes.

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Martínez-Maqueda D
  • López-Díez JJ
  • Recio I

Grupos

Abstract

The potential of bovine lactoferrin (LF) as a source of antihypertensive peptides acting on the renin-angiotensin system (RAS) and the endothelin (ET) system as dual vasopeptidase inhibitors has been examined. For this purpose enzymatic LF hydrolyzates (LFHs) were generated by trypsin and proteinase K digestions. Permeate fractions with molecular masses lower than 3 kDa (LFH <3 kDa) were orally administered to spontaneously hypertensive rats (SHRs). Although both LFHs <3 kDa showed in vitro angiotensin I-converting enzyme (ACE)-inhibitory activity, only proteinase K LFH <3 kDa exerted an in vivo antihypertensive effect. The proteinase K LFH <3 kDa and a previously characterized pepsin LFH <3 kDa with ACE-inhibitory and antihypertensive effects were tested in ex vivo functional assays as inhibitors of ACE-dependent vasoconstriction. Pepsin LFH <3 kDa but not proteinase K LFH <3 kDa inhibited ACE-dependent vasoconstriction. When tested as inhibitors towards endothelin-converting enzyme (ECE), both LFHs <3 kDa exerted in vitro inhibitory effects on ECE activity and inhibited ECE-dependent vasoconstriction. Most abundant peptides in proteinase K LFH <3 kDa were identified by using an ion trap mass spectrometer. Based on peptide abundance, two peptides (GILRPY and REPYFGY) were chemically synthesized and their ECE-inhibitory activity was tested. Both exerted in vitro inhibitory effects on ECE activity. In conclusion, orally effective antihypertensive LFHs <3 kDa may act as dual vasopeptidase (ACE/ECE) or as single ECE inhibitors with different antivasoconstrictor effects depending on the protease used to release bioactive peptide sequences.

Datos de la publicación

ISSN/ISSNe:
0308-8146, 1873-7072

FOOD CHEMISTRY  ELSEVIER SCI LTD

Tipo:
Article
Páginas:
994-1000
Factor de Impacto:
1,554 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 43

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Proyectos asociados

RED DE INVESTIGACION (RENEVAS)

Investigador Principal: ENRIQUE ALBORCH DOMÍNGUEZ

RD06/0026/0006 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006

MICROCLUSTERS-CALIDAD, SEGURIDAD Y FUNCIONALIDAD DE ALIMENTOS

Investigador Principal: JOSÉ LUIS MULLOR SANJOSÉ

2011_0171_VLC/CAMPUS_MCI_MULLOR_SALOM . 2011

INFLUENCIA DE LA DIABETES SOBRE LAS VIAS DE SEÑALIZACION DE LOS RECEPTORES ESTROGENICOS CEREBRALES EN EL ICTUS ISQUEMICO AGUDO EXPERIMENTAL: IMPLICACIONES TERAPEUTICAS

Investigador Principal: GERMÁN TORREGROSA BERNABÉ

PI12/00145 . INSTITUTO DE SALUD CARLOS III . 2013

ENFERMEDADES VASCULARES CEREBRALES (ICTUS)

Investigador Principal: JUAN BAUTISTA SALOM SANVALERO

RD12/0014/0004 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

Cita

Compartir